GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

bit.bio specializes in synthetic biology for human health, providing a platform for deterministic cell programming and manufacturing human cell types at scale with precision and consistency.

bit.bio

BlueRock Therapeutics LP is a clinical stage cell therapy company that investigates the potential of cell therapy to replace cells damaged or lost to disease in order to create medicines in a new way. Self-described as striving to transform the treatment of degenerative diseases.

BlueRock Therapeutics LP

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Metric
Company Name	GC Therapeutics	bit.bio	BlueRock Therapeutics LP	Celldex Therapeutics, Inc.
Symbol				CLDX
MSH ID	COM:GC-TX	BIO:BIT	COM:BLUEROCKTX	COM:CELLDEX
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	GB	US	US
Stage	Series A
Employee Count				160
Website	gc-tx.com	bit.bio	bluerocktx.com	celldex.com
LinkedIn				celldex-therapeutics
Founders

Metric
Market Cap		2.41B
Enterprise Value
Monthly Web Traffic	1.68K
Web Traffic Growth	-0.43
Valuation
Raised Capital	65M

Metric
Revenue				6.88M
Revenue (LTM)
Revenue (NTM)
Gross Profit				3.88M
EBITDA				-139.03M
Operating Income				-142.04M
Net Income				-141.43M
EPS				-2.92
Diluted EPS				-2.92
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.72
Operating Profit Margin				-18.41
EBITDA Margin				-20.20
Net Profit Margin				-18.09
Return on Equity				-0.26
Return on Assets				-0.17
Return on Capital Employed				-0.17

COM:GC-TX

GC Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-15.31
P/B Ratio				7.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				483.69
EV Multiple				-11.72

Metric
Days Sales Outstanding				21.07
Days Payables Outstanding
Days Inventory Outstanding				0.00
Operating Cycle				443.09
Cash Conversion Cycle				56.95
Asset Turnover				0.01

Metric
Operating Cash Flow				-107.29M
Free Cash Flow				-109.11M
Cash Flow to Debt				-38.64
Operating Cash Flow/Sales				-11.10
Free Cash Flow Yield				-0.05

Metric
Cash & Equivalents				34.81M
Accounts Receivable				-2.28M
Inventory
Goodwill
Debt to Capitalization				0.01
Debt to Assets				0.01
Current Ratio				8.84
Quick Ratio				31.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				4.85
R&D to Revenue				25.31
SG&A to Revenue				6.57